AbbVie, Johnson & Johnson, and Abbott Laboratories have impeccable dividend programs. All three are among the largest ...

However, AbbVie has also built a substantial oncology franchise with products like Imbruvica and Venclexta. Some key oncology ...

AbbVie has announced that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.Capstan's lead ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013.

AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter. AbbVie announced its second-quarter results on July 31. It beat estimates for ...

AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira. However, AbbVie has also built a substantial oncology franchise with products ...

AbbVie's lineup features a range of other medicines that are helping drive top-line growth, such as Qulipta for migraine, and cancer drug Venclexta.

Despite the findings, existing data around cardiovascular risk in chronic lymphocytic leukemia (CLL) are limited, and more ...

AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year as higher sales of Venclexta and contributions from new drugs, Elahere ...